Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | RORC | P51449 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 3/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 3/20 | 0.39 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.37 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26981939 | 0.87 | NPSR1 (0.48) | MAPTSMN1; SMN2MEN1KMT2ACYP2C19 | |
| SCHEMBL16112282 | 0.87 | RORC (0.40) | MAPTRORCSMN1; SMN2MEN1KMT2A | |
| SCHEMBL21777929 | 0.87 | EPHX2 (0.43) | SMN1; SMN2EPHX2PPARGKCNQ2KCNQ3 | |
| SCHEMBL21789094 | 0.85 | PPARG (0.44) | SMN1; SMN2EPHX2PPARGKCNQ2KCNQ3 | |
| SCHEMBL26981951 | 0.84 | ALDH1A1 (0.41) | RORCSMN1; SMN2MEN1KMT2ACYP2C19 | |
| SCHEMBL30069764 | 0.84 | ALDH1A1 (0.41) | RORCSMN1; SMN2MEN1KMT2ACYP2C19 | |
| SCHEMBL29116612 | 0.83 | PPARG (0.41) | MAPTEPHX2PPARGKCNQ2KCNQ3 | |
| SCHEMBL29789103 | 0.82 | MAPT (0.47) | MAPTRORCSMN1; SMN2MEN1KMT2A | |
| SCHEMBL21788887 | 0.82 | MAPT (0.47) | MAPTRORCSMN1; SMN2MEN1KMT2A | |
| SCHEMBL21789124 | 0.82 | EPHX2 (0.47) | MAPTMEN1KMT2AEPHX2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276976-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2025-09-04 | — | — | US | disclosed |
| CN-119998292-A | Crystalline forms of 5- (3, 4-difluorobenzyl) -8- ((1 r,4 r) -4-methylcyclohexyl) -6, 9-dioxo-2, 5, 8-triazaspiro [3.5] nonane-2-carbaldehyde | 赛特凯恩蒂克公司 | 2025-05-13 | — | — | CN | disclosed |
| US-12275741-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-20240368172-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2024-11-07 | — | — | US | disclosed |
| US-11952381-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| EP-4301760-A1 | CARDIAC SARCOMERE INHIBITORS | Cytokinetics, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| US-20230090256-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2023-03-23 | — | — | US | disclosed |
| WO-2022187501-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| US-11414424-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| US-11414424-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| EP-3843842-A1 | CARDIAC SARCOMERE INHIBITORS | Cytokinetics, Inc. (US) | 2021-07-07 | — | — | EP | disclosed |
| CN-112867539-A | Cardiac muscle segment inhibitor | 赛特凯恩蒂克公司 | 2021-05-28 | — | — | CN | disclosed |
| US-20200109148-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2020-04-09 | — | — | US | disclosed |
| US-20200109148-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2020-04-09 | — | — | US | disclosed |
| WO-2020047447-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. (US) | 2020-03-05 | — | — | WO | disclosed |
| WO-2020047447-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. (US) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11414424-B2 | Cardiac sarcomere inhibitors | TNNI3, MYLK2, TNNT2 | MAPT 2089/4885RORC 4575/4885SMN1; SMN2 96/4885 |
| US-20200109148-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, MYLK2, TNNT2 | MAPT 2089/4885RORC 4575/4885SMN1; SMN2 96/4885 |
| US-20230090256-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, MYLK2, TNNT2 | MAPT 2089/4885RORC 4575/4885SMN1; SMN2 96/4885 |
| US-12275741-B2 | Cardiac sarcomere inhibitors | TNNI3, MYLK2, TNNT2 | MAPT 2089/4885RORC 4575/4885SMN1; SMN2 96/4885 |
| US-20240368172-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, MYLK2, TNNT2 | MAPT 2089/4885RORC 4575/4885SMN1; SMN2 96/4885 |
| US-20250276976-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, MYLK2, TNNT2 | MAPT 2089/4885RORC 4575/4885SMN1; SMN2 96/4885 |
| US-11952381-B2 | Cardiac sarcomere inhibitors | TNNI3, MYLK2, TNNT2 | MAPT 2089/4885RORC 4575/4885SMN1; SMN2 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.